The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the…
Researchers develop AI Tool, Sybil, to Predict Lung Cancer Risk
A new study has been conducted by investigators from the Mass General Cancer Center in collaboration with researchers at the Massachusetts Institute of Technology (MIT) to develop and test an Artificial Intelligence…
Sarunashi Fruit May Inhibit Lung Cancer Growth, Study Finds
The researchers from Okayama University in Japan have found evidence that ingesting juice from sarunashi fruit can help prevent and reduce lung cancer via a mouse model. Lung cancer is the second…
Novocure and Zai Lab Announces Pivotal LUNAR Study in NSCLC
Zai Lab Limited and Novocure have announced the LUNAR study met its primary endpoint. It demonstrates statistically significant and clinically meaningful improvement in overall survival. LUNAR is a pivotal study to test…
Lung Cancer Increased by 5% in Last Two Years: Central Govt India
The disease of lung cancer is a significant health concern all around the world. Its alarming rise is becoming serious issue among people of all ages. According to the govt figures, Lung…
Columbia Biomedical Engineers Develop New Bacterial Therapy for Lung Cancer Treatment
Lung cancer is one of the most deadly types of cancers in the United States as well as around the world. As most of the therapies have been ineffective, this leaves patients…
U.S. FDA Approves Lung Cancer Drug, Adagrasib
The US Food and Drug Administration (FDA) has granted accelerated approval for Mirati Therapeutics’ Krazati (adagrasib) for treatment of mutated locally advanced or metastatic non-small cell lung cancer in adults. This accelerated…
Breathe Test to Detect Lung Cancer, Scientists Suggests
Lung cancer is one of the most common types of cancers all around the world and has the highest death rate. The reason behind high death rate is that it is often…